Document is current
Any future updates will be listed below
-
Authors
Stanescu, Sinziana http://orcid.org/0000-0003-0340-4580
Bravo-Alonso, Irene
Belanger-Quintana, Amaya
Pérez, Belen
Medina-Diaz, Montserrat
Ruiz-Sala, Pedro
Flores, Nathaly Paola
Buenache, Raquel
Arrieta, Francisco
Rodríguez-Pombo, Pilar
-
Funding
Funding for this research was provided by:
European Regional Development Fund (PI19/01155, B2017/BMD-3721)
Fundación Ramón Areces (CIVP17A2827)
- License Information
-
More Information
Article History
Received: 3 March 2022
Accepted: 6 June 2022
First Online: 21 June 2022
Declarations
:
: The study protocol adhered to the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of <i>Universidad Autónoma de Madrid</i> (CEI-105-2052). No animals were used in this study. Written informed consent to be include in this study was provided by the patient's parents.
: Written informed consent for publication was provided by the patient's parents.
: SS has received travel and speaker fees from Nutricia, Mead Johnson, Genzyme, Recordatti Rare Diseases, Vitaflo-Nestlé, BioMarin. IBA declares that she has no conflict of interest. ABQ has received travel and speaker fees from Nutricia, Mead Johnson, Genzyme, Recordatti Rare Diseases, Vitaflo-Nestlé, Takeda, BioMarin; advisory fees from BioMarin and Merk Serono. FA has received travel and speaker fees from Nutricia, Mead Johnson, Recordatti Rare Diseases, Vitaflo-Nestlé, BioMarin. MMD declares that she has no conflict of interest. PRS declares that she has no conflict of interest. BP declares that she has no conflict of interest. NPF declares that she has no conflict of interest. RB declares that she has no conflict of interest. PRP declares that she has no conflict of interest.
